Awfis Reports Doubling of Q4 Profit to Rs 23 Crore Revenue Surges Bitcoin Below 100000 Market Dynamics and Investor Considerations Berenberg Economist Warns ECB Rate Hikes a Big Mistake Amid Stagflation Concerns SpaceX Files for IPO Under Ticker SPCX Could Boost Elon Musks Trillionaire Status Treasury Yield Surge Challenges RiskFree Asset Assumptions as Geopolitical Tensions and Inflation Reshape Fed Policy Outlook Andy Burnhams Political Rise Implications for UK Regional Investment and Devolution Policy EIKN Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Stage JBS Q1 2026 Earnings EPS Miss Drags on Stock Despite Resilient Operations West Pharmaceutical Services WST Q1 2026 Earnings Strong EPS Surprise of 258 Outpaces Estimates LCI Industries Q1 2026 Earnings EPS Surprises by 157 as Shares Rise Fortrea Holdings Inc FTRE Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction CBRL Q1 2026 Earnings Profitability Surprise as EPS Crushes Estimates Zevra Therapeutics ZVRA Gains Momentum Breaks Above 10 Amid Bullish Volume Sprinklr Inc CXM Gains 256 as Stock Tests Key Resistance Level NHPAP Preferred Stock Holds Steady Near Support Amid Quiet Trading ANSCW Warrants Hold Steady at 023 Amid Consolidation Fractyl Health GUTS Dips 3 as Stock Hovers Near Critical Support at 085 Consumer Sentiment Slips to Fresh Record Low in May Amid Surging Gas Prices and Geopolitical Tensions SPFI Q1 2026 Earnings EPS Misses Estimates Stage Set for Cautious Outlook Daktronics DAKT Surges 284 as Shares Approach Resistance Amid Strong Volume MOLN Q4 2025 Earnings NarrowerThanExpected Loss Highlights Cost Control But Stock Edges Lower Nerdy Inc Q1 2026 Earnings Narrowed Loss Beats Estimates Stock Jumps 53 WES Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency HOLX Q1 2026 Earnings EPS Falls Short of Expectations by 645 LULU Q1 2026 Earnings EPS Surprise Shows Resilience Amid Tepid Market Response CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment RLAY Q1 2026 Earnings EPS Misses Consensus PreRevenue Biotech Maintains RD Focus